Immuneering Corporation (IMRX) Quote

Position at 2.22, a little late, but still a 400% gainers,,, GLTA(LOAD NOW PEEPS)

IMRX..........................................https://stockcharts.com/h-sc/ui?s=IMRX&p=W&b=5&g=0&id=p86431144783

IMRX...$2.54...🥳... 50MA readies for the 100MA Cross...Then both will Cross the 200MA...This should take us to $7 range...imo we shall see ...Accumulation and Money Flow on the rise... https://schrts.co/JIPTdrQz

Took profit from $2.55 to $2.90 and still holding 25% of my shares...will be adding all dips...

"W" Pattern in play here...Watch for some consolidation followed by the Double Top Breakout at $3.80 range...If this plays out then we see $7 range...imo...we shall see...

IMRX...$2.52...Trying to shake shares here...🥳

IMRX...$2.96...Hod...🥳

georgie18

Member Level
Re: georgie18 post# 686256

Wednesday, June 18, 2025 12:18:40 PM

Post#
686320
of 686363
IMRX...$2.52...🥳

georgie18

Member Level
Re: georgie18 post# 394514

Wednesday, June 18, 2025 9:37:41 AM

Post#
394519
of 394537
IMRX...$2.19...🥳...Hod...

IMRX...$1.97...🥳

georgie18

Member Level
Re: georgie18 post# 394472

Tuesday, June 17, 2025 4:04:27 PM

Post#
394503
of 394513
IMRX...$1.83...🥳... https://schrts.co/dSUxnurH ...Oversold 30 minute Chart and a Reversal Hammer off the bottom...Loaded the $1.70 range dip...

IMRX...$2.52...🥳

georgie18

Member Level
Re: georgie18 post# 394514

Wednesday, June 18, 2025 9:37:41 AM

Post#
394519
of 394537
IMRX...$2.19...🥳...Hod...

IMRX...$1.97...🥳

georgie18

Member Level
Re: georgie18 post# 394472

Tuesday, June 17, 2025 4:04:27 PM

Post#
394503
of 394513
IMRX...$1.83...🥳... https://schrts.co/dSUxnurH ...Oversold 30 minute Chart and a Reversal Hammer off the bottom...Loaded the $1.70 range dip...

IMRX...$2.19...🥳...Hod...

IMRX...$1.97...🥳

georgie18

Member Level
Re: georgie18 post# 394472

Tuesday, June 17, 2025 4:04:27 PM

Post#
394503
of 394513
IMRX...$1.83...🥳... https://schrts.co/dSUxnurH ...Oversold 30 minute Chart and a Reversal Hammer off the bottom...Loaded the $1.70 range dip...

IMRX...$1.97...🥳

georgie18

Member Level
Re: georgie18 post# 394472

Tuesday, June 17, 2025 4:04:27 PM

Post#
394503
of 394513
IMRX...$1.83...🥳... https://schrts.co/dSUxnurH ...Oversold 30 minute Chart and a Reversal Hammer off the bottom...Loaded the $1.70 range dip...

IMRX...$1.83...🥳... https://schrts.co/dSUxnurH ...Oversold 30 minute Chart and a Reversal Hammer off the bottom...Loaded the $1.70 range dip...

IMRX...$1.98...is being loaded... https://schrts.co/vPRZtcuu

IMRX...$2.42...🥳... https://schrts.co/itNUUBND ...Should see some more traction on that news...Like to see a Double Top Breakout at $3.80 range...

IMRX...$3.11...🥳... https://finviz.com/news/82017/immuneering-reports-positive-overall-survival-data-for-atebimetinib-imm-1-104-from-ongoing-phase-2a-trial-in-first-line-pancreatic-cancer-patients

georgie18

Member Level
Re: georgie18 post# 137

Monday, June 16, 2025 1:32:33 PM

Post#
138
of 138
IMRX...$2.35...🥳

georgie18

Member Level
Re: georgie18 post# 389758

Monday, June 16, 2025 8:31:26 AM

Post#
394384
of 394426
IMRX...$2.15...🥳... CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that it will host a conference call and live webcast at 8:00 am ET on June 17, 2025. The company is excited to provide updates from its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients.

The conference call will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

IMRX...$2.35...🥳

georgie18

Member Level
Re: georgie18 post# 389758

Monday, June 16, 2025 8:31:26 AM

Post#
394384
of 394426
IMRX...$2.15...🥳... CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that it will host a conference call and live webcast at 8:00 am ET on June 17, 2025. The company is excited to provide updates from its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients.

The conference call will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

IMRX...$2.15...🥳... CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that it will host a conference call and live webcast at 8:00 am ET on June 17, 2025. The company is excited to provide updates from its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients.

The conference call will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

IMRX.......................................https://stockcharts.com/h-sc/ui?s=IMRX&p=W&b=5&g=0&id=p86431144783

IMRX under $2

The company plans to announce progression-free survival data from over 30 first-line pancreatic cancer patients in Q2'25 and initiate a Phase 3 trial in 2026

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
May 5, 2025

- Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 trial planned for announcement in 2Q’25 -
Pancreatic Cancer Patient Passes 13-month Mark on IMM-1-104 Monotherapy: In April, Immuneering provided an update on a Phase 1 pancreatic cancer patient in the third-line setting who has been receiving IMM-1-104 monotherapy for more than 13 months and is still on treatment. The patient – who previously experienced disease progression on first-line FOLFIRINOX and second-line Gem/Cis/nab-Pac – has been on IMM-1-104 monotherapy at 240 mg once daily and maintained stable disease including a RECIST SLD change of -28% and a 91% reduction in peak CA 19-9 levels. Treatment continued to be well tolerated by the patient, with approximately 16% weight gain.

- Reported positive data from the Company’s ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer, and as monotherapy in second-line pancreatic cancer -

- Announced clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo® (cemiplimab) in non-small cell lung cancer -

- Named industry veteran Dr. Igor Matushansky as Chief Medical Officer, to lead clinical efforts as the Company ramps up planning for Phase 3 trial in first line pancreatic cancer -

- Cash runway extended into 2026 -

Cash Position: Cash and cash equivalents as of March 31, 2025, were $35.9 million, compared with $36.1 million as of December 31, 2024.
Net Loss: Net loss attributable to common stockholders was $15.0 million, or $0.42 per share, for the first quarter ended March 31, 2025, compared to $14.3 million, or $0.49 per share, for the first quarter ended March 31, 2024.

https://ir.immuneering.com/news-releases/news-release-details/immuneering-reports-first-quarter-2025-financial-results-and

IMRX under $2

IMRX

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates


https://ir.immuneering.com/news-releases/news-release-details/immuneering-reports-fourth-quarter-and-full-year-2024-financial

It changed from March 6 to March 14.

pancreatic cancer-We observed target lesion shrinkage across all evaluable patients, including a 100% reduction, a rare event in this patient population.”

Further IMM-1-104 Phase 2a data expected in the second quarter of 2025

unexploded bomb------

https://ir.immuneering.com/news-releases/news-release-details/immuneering-provides-positive-update-phase-2a-arm-studying-imm-1

IMRX 10Q due Monday 2/24

IMRX...$1.99...🥳... https://www.globenewswire.com/news-release/2025/02/06/3021891/0/en/Immuneering-Announces-Clinical-Supply-Agreement-with-Regeneron-Pharmaceuticals-to-Evaluate-IMM-1-104-in-Combination-with-Libtayo-cemiplimab.html

MEK inhibitor IMM-1-104 shows promise in pancreatic cancer: Data

One person saw a 100% reduction in their tumor, which Zeskind said is “a rare event in this patient population.”

As of a cut-off date of Dec. 5, the three trial arms involving pancreatic cancer patients had enrolled more than 75 participants. The recent analyses included patients who had received their first dose of treatment at least 14 weeks before the cut-off.

In one trial arm, participants were given first-line treatment with daily IMM-1-104 (240 or 320 mg) along with a modified regimen of gemcitabine with nab-paclitaxel (GnP), a standard chemotherapy regimen used in pancreatic cancer.

Data showed that the overall response rate (ORR) was 43%, with three of seven treated patients achieving partial or complete cancer shrinkage. Six of the seven participants (86%) achieved controlled disease, where the cancer has shrunk or remained stable. Benchmark data from a Phase 3 trial testing mGnP alone as a first-line pancreatic cancer treatment was associated with an ORR of 23% and a disease control rate 48%.

In another arm, patients were treated with a combination of daily IMM-1-104 (240 mg) along with a modified regimen of FOLFIRINOX as a first-line treatment. FOLFIRINOX is a combination of four chemotherapy agents – leucovorin (folinic acid), fluorouracil, irinotecan hydrochloride, and oxaliplatin.

All four evaluable patients achieved a shrinkage of their target tumors and disease control.
The final arm of the Phase 2b trial tested once daily IMM-1-104 monotherapy (320 mg) as a second-line treatment in pancreatic cancer patients. Results showed that 11 of 21 treated patients achieved disease control, including ten people with stable disease and one person who experienced a 67% shrinkage in their target tumor.

The therapy showed a good tolerability profile across treatment arms, with common side effects including diarrhea, fatigue, and nausea.

“Having demonstrated compelling activity in both the combination and monotherapy settings for pancreatic cancer, the emerging tolerability profile for IMM-1-104 is also highly promising,” said Brett Hall, PhD, chief scientific officer of Immuneering. “The maturing safety profile for IMM-1-104 gives us confidence that Immuneering may have developed a better tolerated MEK-inhibitor,” Hall said.

https://rarecancernews.com/news/mek-inhibitor-imm-1-104-shows-promise-pancreatic-cancer-data/

news- Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer -

https://ir.immuneering.com/news-releases/news-release-details/immuneering-provides-positive-update-phase-2a-arm-studying-imm-1

IMRX...$2.05...🥳...https://www.globenewswire.com/news-release/2025/01/13/3008480/0/en/Immuneering-Provides-Positive-Update-on-Phase-2a-Arm-Studying-IMM-1-104-in-Combination-with-Modified-FOLFIRINOX-for-First-Line-Pancreatic-Cancer.html

georgie18

Member Level
Re: georgie18 post# 388208

Wednesday, January 08, 2025 1:43:43 PM

Post#
388288
of 388415
IMRX...Added on the $1.90 dip...🥳...to my $2.50 dip buys...Last alert ran to $5 range from $2 range...

georgie18

Member Level
Re: georgie18 post# 114

Tuesday, January 07, 2025 1:34:26 PM

Post#
119
of 119
IMRX...$2.50 ...Back in here...🥳

georgie18

Member Level
Re: georgie18 post# 388149

Tuesday, January 07, 2025 7:57:09 AM

Post#
388152
of 388207
IMRX...$4.75...🥳Took the other 1/2 off the table...from my $1.50 range shares...

georgie18

Member Level
Re: georgie18 post# 106

Tuesday, January 07, 2025 7:37:48 AM

Post#
110
of 113
IMRX...$3.67...🥳...Taking 1/2 off the table here from my $1.52 Alert...

georgie18

Member Level
Re: georgie18 post# 387979

Monday, January 06, 2025 1:24:01 PM

Post#
388095
of 388148
IMRX...$2.52...Off the $1.52 Gap Fill Alert...🥳

georgie18

Member Level
Re: georgie18 post# 103

Friday, January 03, 2025 2:26:33 PM

Post#
105
of 105
IMRX...$2.37...🥳...Trying for Upper Bollie Breakout here...Off the $1.52 Gap Fill Alert...

georgie18

Member Level
Re: georgie18 post# 387313

Friday, December 20, 2024 1:41:08 PM

Post#
387324
of 387978
IMRX...$2.08...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 100

Friday, December 20, 2024 12:44:19 PM

Post#
102
of 102
IMRX...$2.00...🥳...Tring to Breakout here...Off the $15.2 range Gap Fill...

georgie18

Member Level
Re: georgie18 post# 386949

Monday, December 16, 2024 9:52:41 AM

Post#
386990
of 387312
IMRX...$1.75...🥳...Bouncing off the Gap fill...Looking to fill the Gap up top in the $1.90 Range...

georgie18

Member Level
Re: georgie18 post# 98

Friday, December 13, 2024 2:49:56 PM

Post#
99
of 99
IMRX...$1.52...Gap filled...🥳...Open Gap up in the $1.90 range...that will fill...

georgie18

Member Level
Re: georgie18 post# 384375

Friday, December 13, 2024 9:47:27 AM

Post#
386929
of 386949
IMRX...$1.72...🥳...On the Gap fill...

georgie18

Member Level
Re: georgie18 post# 84

Tuesday, October 15, 2024 8:48:58 AM

Post#
86
of 97
IMRX...$2.58 ...on News...$1.86 Dip partially filled the gap...🥳

CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.

Yup...until they get bought out...🥳...imo...we shall see...

Added $2.02 but warned folks this is traditional on this stock with news get out premarket add some back on post news beat down

IMRX...Added on the $1.90 dip...🥳...to my $2.50 dip buys...Last alert ran to $5 range from $2 range...

georgie18

Member Level
Re: georgie18 post# 114

Tuesday, January 07, 2025 1:34:26 PM

Post#
119
of 119
IMRX...$2.50 ...Back in here...🥳

georgie18

Member Level
Re: georgie18 post# 388149

Tuesday, January 07, 2025 7:57:09 AM

Post#
388152
of 388207
IMRX...$4.75...🥳Took the other 1/2 off the table...from my $1.50 range shares...

georgie18

Member Level
Re: georgie18 post# 106

Tuesday, January 07, 2025 7:37:48 AM

Post#
110
of 113
IMRX...$3.67...🥳...Taking 1/2 off the table here from my $1.52 Alert...

georgie18

Member Level
Re: georgie18 post# 387979

Monday, January 06, 2025 1:24:01 PM

Post#
388095
of 388148
IMRX...$2.52...Off the $1.52 Gap Fill Alert...🥳

georgie18

Member Level
Re: georgie18 post# 103

Friday, January 03, 2025 2:26:33 PM

Post#
105
of 105
IMRX...$2.37...🥳...Trying for Upper Bollie Breakout here...Off the $1.52 Gap Fill Alert...

georgie18

Member Level
Re: georgie18 post# 387313

Friday, December 20, 2024 1:41:08 PM

Post#
387324
of 387978
IMRX...$2.08...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 100

Friday, December 20, 2024 12:44:19 PM

Post#
102
of 102
IMRX...$2.00...🥳...Tring to Breakout here...Off the $15.2 range Gap Fill...

georgie18

Member Level
Re: georgie18 post# 386949

Monday, December 16, 2024 9:52:41 AM

Post#
386990
of 387312
IMRX...$1.75...🥳...Bouncing off the Gap fill...Looking to fill the Gap up top in the $1.90 Range...

georgie18

Member Level
Re: georgie18 post# 98

Friday, December 13, 2024 2:49:56 PM

Post#
99
of 99
IMRX...$1.52...Gap filled...🥳...Open Gap up in the $1.90 range...that will fill...

georgie18

Member Level
Re: georgie18 post# 384375

Friday, December 13, 2024 9:47:27 AM

Post#
386929
of 386949
IMRX...$1.72...🥳...On the Gap fill...

georgie18

Member Level
Re: georgie18 post# 84

Tuesday, October 15, 2024 8:48:58 AM

Post#
86
of 97
IMRX...$2.58 ...on News...$1.86 Dip partially filled the gap...🥳

CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.

IMRX...$2.50 ...Back in here...🥳

georgie18

Member Level
Re: georgie18 post# 388149

Tuesday, January 07, 2025 7:57:09 AM

Post#
388152
of 388207
IMRX...$4.75...🥳Took the other 1/2 off the table...from my $1.50 range shares...

georgie18

Member Level
Re: georgie18 post# 106

Tuesday, January 07, 2025 7:37:48 AM

Post#
110
of 113
IMRX...$3.67...🥳...Taking 1/2 off the table here from my $1.52 Alert...

georgie18

Member Level
Re: georgie18 post# 387979

Monday, January 06, 2025 1:24:01 PM

Post#
388095
of 388148
IMRX...$2.52...Off the $1.52 Gap Fill Alert...🥳

georgie18

Member Level
Re: georgie18 post# 103

Friday, January 03, 2025 2:26:33 PM

Post#
105
of 105
IMRX...$2.37...🥳...Trying for Upper Bollie Breakout here...Off the $1.52 Gap Fill Alert...

georgie18

Member Level
Re: georgie18 post# 387313

Friday, December 20, 2024 1:41:08 PM

Post#
387324
of 387978
IMRX...$2.08...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 100

Friday, December 20, 2024 12:44:19 PM

Post#
102
of 102
IMRX...$2.00...🥳...Tring to Breakout here...Off the $15.2 range Gap Fill...

georgie18

Member Level
Re: georgie18 post# 386949

Monday, December 16, 2024 9:52:41 AM

Post#
386990
of 387312
IMRX...$1.75...🥳...Bouncing off the Gap fill...Looking to fill the Gap up top in the $1.90 Range...

georgie18

Member Level
Re: georgie18 post# 98

Friday, December 13, 2024 2:49:56 PM

Post#
99
of 99
IMRX...$1.52...Gap filled...🥳...Open Gap up in the $1.90 range...that will fill...

georgie18

Member Level
Re: georgie18 post# 384375

Friday, December 13, 2024 9:47:27 AM

Post#
386929
of 386949
IMRX...$1.72...🥳...On the Gap fill...

georgie18

Member Level
Re: georgie18 post# 84

Tuesday, October 15, 2024 8:48:58 AM

Post#
86
of 97
IMRX...$2.58 ...on News...$1.86 Dip partially filled the gap...🥳

CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.

IMRX: Yep, they like to do stuff like that! (Glad I grabbed some @HOTH, when it suddenly popped-up at the bottom of Benzinga's cute little Pre-Market list!!)

One more round back in at $2.60s they always beat this one down at market bell and you have to look for the beat down price lol. Second round not as profitable but take it

$IMRX reported Phase 2a data for IMM-1-104 in pancreatic cancer, showing 43% ORR and 86% DCR in 1st-line Gemcitabine/nab-paclitaxel combo, with tumor shrinkage in all patients on FOLFIRINOX combo, and 52% disease control in 2nd-line monotherapy. Favorable safety profile supports its potential as a better-tolerated MEK inhibitor for RAS-driven tumors. Further combination data expected in 2Q 2025.

IMRX: WOW!!

IMRX...$4.75...🥳Took the other 1/2 off the table...from my $1.50 range shares...

georgie18

Member Level
Re: georgie18 post# 106

Tuesday, January 07, 2025 7:37:48 AM

Post#
110
of 113
IMRX...$3.67...🥳...Taking 1/2 off the table here from my $1.52 Alert...

georgie18

Member Level
Re: georgie18 post# 387979

Monday, January 06, 2025 1:24:01 PM

Post#
388095
of 388148
IMRX...$2.52...Off the $1.52 Gap Fill Alert...🥳

georgie18

Member Level
Re: georgie18 post# 103

Friday, January 03, 2025 2:26:33 PM

Post#
105
of 105
IMRX...$2.37...🥳...Trying for Upper Bollie Breakout here...Off the $1.52 Gap Fill Alert...

georgie18

Member Level
Re: georgie18 post# 387313

Friday, December 20, 2024 1:41:08 PM

Post#
387324
of 387978
IMRX...$2.08...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 100

Friday, December 20, 2024 12:44:19 PM

Post#
102
of 102
IMRX...$2.00...🥳...Tring to Breakout here...Off the $15.2 range Gap Fill...

georgie18

Member Level
Re: georgie18 post# 386949

Monday, December 16, 2024 9:52:41 AM

Post#
386990
of 387312
IMRX...$1.75...🥳...Bouncing off the Gap fill...Looking to fill the Gap up top in the $1.90 Range...

georgie18

Member Level
Re: georgie18 post# 98

Friday, December 13, 2024 2:49:56 PM

Post#
99
of 99
IMRX...$1.52...Gap filled...🥳...Open Gap up in the $1.90 range...that will fill...

georgie18

Member Level
Re: georgie18 post# 384375

Friday, December 13, 2024 9:47:27 AM

Post#
386929
of 386949
IMRX...$1.72...🥳...On the Gap fill...

georgie18

Member Level
Re: georgie18 post# 84

Tuesday, October 15, 2024 8:48:58 AM

Post#
86
of 97
IMRX...$2.58 ...on News...$1.86 Dip partially filled the gap...🥳

CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.

Nice...🥳...I am holding 1/2 for now...

Nice to log on and see this move...🥳

Rest out $4s hit 4.12 

IMRX...$3.67...🥳...Taking 1/2 off the table here from my $1.52 Alert...

georgie18

Member Level
Re: georgie18 post# 387979

Monday, January 06, 2025 1:24:01 PM

Post#
388095
of 388148
IMRX...$2.52...Off the $1.52 Gap Fill Alert...🥳

georgie18

Member Level
Re: georgie18 post# 103

Friday, January 03, 2025 2:26:33 PM

Post#
105
of 105
IMRX...$2.37...🥳...Trying for Upper Bollie Breakout here...Off the $1.52 Gap Fill Alert...

georgie18

Member Level
Re: georgie18 post# 387313

Friday, December 20, 2024 1:41:08 PM

Post#
387324
of 387978
IMRX...$2.08...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 100

Friday, December 20, 2024 12:44:19 PM

Post#
102
of 102
IMRX...$2.00...🥳...Tring to Breakout here...Off the $15.2 range Gap Fill...

georgie18

Member Level
Re: georgie18 post# 386949

Monday, December 16, 2024 9:52:41 AM

Post#
386990
of 387312
IMRX...$1.75...🥳...Bouncing off the Gap fill...Looking to fill the Gap up top in the $1.90 Range...

georgie18

Member Level
Re: georgie18 post# 98

Friday, December 13, 2024 2:49:56 PM

Post#
99
of 99
IMRX...$1.52...Gap filled...🥳...Open Gap up in the $1.90 range...that will fill...

georgie18

Member Level
Re: georgie18 post# 384375

Friday, December 13, 2024 9:47:27 AM

Post#
386929
of 386949
IMRX...$1.72...🥳...On the Gap fill...

georgie18

Member Level
Re: georgie18 post# 84

Tuesday, October 15, 2024 8:48:58 AM

Post#
86
of 97
IMRX...$2.58 ...on News...$1.86 Dip partially filled the gap...🥳

CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.

Flip some out $3.40s 

IMRX $3.08 Dr. Zeskind continued: “Today we are also sharing initial data from IMM-1-104 in combination with modified FOLFIRINOX in first-line pancreatic cancer patients. We observed target lesion shrinkage across all evaluable patients, including a 100% reduction, a rare event in this patient population. Additionally, we are reporting initial data from our monotherapy arm of IMM-1-104 in second-line pancreatic cancer. We saw clear activity, including a partial response with a 67% target lesion reduction. We believe these results provide substantiating evidence of IMM-1-104’s contribution in combination with current therapies.”

News out $3.20s + 34% - Favorable initial data for IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients show target lesion shrinkage in all evaluable patients, including a 100% reduction

IMRX...$2.52...Off the $1.52 Gap Fill Alert...🥳

georgie18

Member Level
Re: georgie18 post# 103

Friday, January 03, 2025 2:26:33 PM

Post#
105
of 105
IMRX...$2.37...🥳...Trying for Upper Bollie Breakout here...Off the $1.52 Gap Fill Alert...

georgie18

Member Level
Re: georgie18 post# 387313

Friday, December 20, 2024 1:41:08 PM

Post#
387324
of 387978
IMRX...$2.08...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 100

Friday, December 20, 2024 12:44:19 PM

Post#
102
of 102
IMRX...$2.00...🥳...Tring to Breakout here...Off the $15.2 range Gap Fill...

georgie18

Member Level
Re: georgie18 post# 386949

Monday, December 16, 2024 9:52:41 AM

Post#
386990
of 387312
IMRX...$1.75...🥳...Bouncing off the Gap fill...Looking to fill the Gap up top in the $1.90 Range...

georgie18

Member Level
Re: georgie18 post# 98

Friday, December 13, 2024 2:49:56 PM

Post#
99
of 99
IMRX...$1.52...Gap filled...🥳...Open Gap up in the $1.90 range...that will fill...

georgie18

Member Level
Re: georgie18 post# 384375

Friday, December 13, 2024 9:47:27 AM

Post#
386929
of 386949
IMRX...$1.72...🥳...On the Gap fill...

georgie18

Member Level
Re: georgie18 post# 84

Tuesday, October 15, 2024 8:48:58 AM

Post#
86
of 97
IMRX...$2.58 ...on News...$1.86 Dip partially filled the gap...🥳

CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.

IMRX...$2.37...🥳...Trying for Upper Bollie Breakout here...Off the $1.52 Gap Fill Alert...

georgie18

Member Level
Re: georgie18 post# 387313

Friday, December 20, 2024 1:41:08 PM

Post#
387324
of 387978
IMRX...$2.08...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 100

Friday, December 20, 2024 12:44:19 PM

Post#
102
of 102
IMRX...$2.00...🥳...Tring to Breakout here...Off the $15.2 range Gap Fill...

georgie18

Member Level
Re: georgie18 post# 386949

Monday, December 16, 2024 9:52:41 AM

Post#
386990
of 387312
IMRX...$1.75...🥳...Bouncing off the Gap fill...Looking to fill the Gap up top in the $1.90 Range...

georgie18

Member Level
Re: georgie18 post# 98

Friday, December 13, 2024 2:49:56 PM

Post#
99
of 99
IMRX...$1.52...Gap filled...🥳...Open Gap up in the $1.90 range...that will fill...

georgie18

Member Level
Re: georgie18 post# 384375

Friday, December 13, 2024 9:47:27 AM

Post#
386929
of 386949
IMRX...$1.72...🥳...On the Gap fill...

georgie18

Member Level
Re: georgie18 post# 84

Tuesday, October 15, 2024 8:48:58 AM

Post#
86
of 97
IMRX...$2.58 ...on News...$1.86 Dip partially filled the gap...🥳

CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.

IMRX......................https://stockcharts.com/h-sc/ui?s=IMRX&p=W&b=5&g=0&id=p86431144783

IMRX...$2.08...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 100

Friday, December 20, 2024 12:44:19 PM

Post#
102
of 102
IMRX...$2.00...🥳...Tring to Breakout here...Off the $15.2 range Gap Fill...

georgie18

Member Level
Re: georgie18 post# 386949

Monday, December 16, 2024 9:52:41 AM

Post#
386990
of 387312
IMRX...$1.75...🥳...Bouncing off the Gap fill...Looking to fill the Gap up top in the $1.90 Range...

georgie18

Member Level
Re: georgie18 post# 98

Friday, December 13, 2024 2:49:56 PM

Post#
99
of 99
IMRX...$1.52...Gap filled...🥳...Open Gap up in the $1.90 range...that will fill...

georgie18

Member Level
Re: georgie18 post# 384375

Friday, December 13, 2024 9:47:27 AM

Post#
386929
of 386949
IMRX...$1.72...🥳...On the Gap fill...

georgie18

Member Level
Re: georgie18 post# 84

Tuesday, October 15, 2024 8:48:58 AM

Post#
86
of 97
IMRX...$2.58 ...on News...$1.86 Dip partially filled the gap...🥳

CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.

IMRX...$2.00...🥳...Tring to Breakout here...Off the $15.2 range Gap Fill...

georgie18

Member Level
Re: georgie18 post# 386949

Monday, December 16, 2024 9:52:41 AM

Post#
386990
of 387312
IMRX...$1.75...🥳...Bouncing off the Gap fill...Looking to fill the Gap up top in the $1.90 Range...

georgie18

Member Level
Re: georgie18 post# 98

Friday, December 13, 2024 2:49:56 PM

Post#
99
of 99
IMRX...$1.52...Gap filled...🥳...Open Gap up in the $1.90 range...that will fill...

georgie18

Member Level
Re: georgie18 post# 384375

Friday, December 13, 2024 9:47:27 AM

Post#
386929
of 386949
IMRX...$1.72...🥳...On the Gap fill...

georgie18

Member Level
Re: georgie18 post# 84

Tuesday, October 15, 2024 8:48:58 AM

Post#
86
of 97
IMRX...$2.58 ...on News...$1.86 Dip partially filled the gap...🥳

CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

https://www.biospace.com/press-releases/immuneering-to-present-data-from-three-arms-of-its-ongoing-phase-2a-trial-of-imm-1-104-in-early-january-2025